Minnesota is currently home to 2091 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
NCT05262270
Recruiting
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2025
Locations: Berman Center for Outcomes and Clinical Research at Hennepin Healthcare, Minneapolis, Minnesota
Conditions: Cocaine Use Disorder
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #107, Rochester, Minnesota
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Hairy Cell Leukemia Patient Data Registry
NCT02560883
Recruiting
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Leukemia, Other
Register for Updates
Parent-Child EF Intervention
NCT06924307
Recruiting
Koronis Biomedical Technologies Corporation (KBT) is developing a cognitive intervention to promote healthy development of Executive Function (EF) skills in young children by leveraging a smartphone-based training regime designed for parents.
Gender:
ALL
Ages:
Between 2 years and 5 years
Trial Updated:
04/10/2025
Locations: University of Minnesota, Institute of Child Development, Minneapolis, Minnesota
Conditions: Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children
Register for Updates
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
NCT06897670
Recruiting
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Register for Updates
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Advanced Solid Tumor
Register for Updates
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
NCT06462365
Recruiting
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
Register for Updates
Increasing Access to Evidence-Based Care in Integrated Behavioral Health
NCT06347822
Recruiting
The purpose of this research is to explore whether a single-session therapy visit may be of interest to patients seeking mental health services in Mayo Clinic's Integrated Behavioral Health program and whether a single-session therapy visit may be helpful in improving mental health. Researchers hope to better understand whether single-session visits could be a helpful option to offer patients in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Psychotherapy
Register for Updates
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316
Recruiting
This is an open-label, multi-center study to evaluate safety, tolerability, and exploratory efficacy of a single dose of intravenously-administered AMT-191. The plan is to investigate 2 sequential dose cohorts with 3-6 Participants per cohort. Participants will continue receiving regularly scheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
04/10/2025
Locations: MHealth Fairview University of Minnesota Medical Center East Bank, Minneapolis, Minnesota
Conditions: Fabry Disease
Register for Updates
Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)
NCT06236711
Recruiting
The researchers are trying to test the feasibility and acceptability of using transcranial Direct Current Stimulation (tDCS) in hospitalized adult patients with Treatment Resistant Depression (TRD), assess for any preliminary effect on depressive and cognitive symptoms, and explore the utility of biomarkers to assess response to tDCS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Treatment Resistant Depression
Register for Updates
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Register for Updates
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037
Recruiting
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Register for Updates